ACUMEN PHARMACEUTICALS INC. ANNOUNCES CLOSE OF FINANCING

Proceeds will continue to fund certain operations into 2016.

Livermore, CA, September 28, 2015 – Acumen Pharmaceuticals, Inc., today announced it has completed a private round of funding that will  fund on-going preclinical development of ACU-193, a monoclonal antibody that selectively binds to and captures soluble oligomers of the amyloid-beta peptide.

NeuroVentures and other existing investors, were joined by PBM Capital LLC in the financing.